Which has higher earnings and valuation, LYEL or ABSI?

Absci has higher revenue and earnings than Lyell Immunopharma. Absci is trading at a lower price-to-earnings ratio than Lyell Immunopharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lyell Immunopharma $40K 8,722.00 -$274.45M -$12.83 N/A Absci $2.80M 501.39 -$115.18M -$0.83 N/A

Is LYEL or ABSI more profitable?

Absci has a net margin of -6,450.76% compared to Lyell Immunopharma's net margin of -920,285.25%. Absci's return on equity of -66.32% beat Lyell Immunopharma's return on equity. Company Net Margins Return on Equity Return on Assets Lyell Immunopharma -920,285.25% -87.60% -67.85% Absci -6,450.76% -66.32% -57.01%

Does the media prefer LYEL or ABSI?

In the previous week, Lyell Immunopharma had 5 more articles in the media than Absci. MarketBeat recorded 7 mentions for Lyell Immunopharma and 2 mentions for Absci. Lyell Immunopharma's average media sentiment score of 0.39 beat Absci's score of 0.00 indicating that Lyell Immunopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lyell Immunopharma 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Absci 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation & earnings, NVAX or LYEL?

Novavax has higher revenue and earnings than Lyell Immunopharma. Novavax is trading at a lower price-to-earnings ratio than Lyell Immunopharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Novavax $1.12B 1.15 $440.30M -$1.52 N/A Lyell Immunopharma $40K 8,722.00 -$274.45M -$12.83 N/A

Does the media refer more to NVAX or LYEL?

In the previous week, Novavax had 18 more articles in the media than Lyell Immunopharma. MarketBeat recorded 25 mentions for Novavax and 7 mentions for Lyell Immunopharma. Lyell Immunopharma's average media sentiment score of 0.39 beat Novavax's score of 0.22 indicating that Lyell Immunopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Novavax 5 Very Positive mention(s) 3 Positive mention(s) 9 Neutral mention(s) 4 Negative mention(s) 1 Very Negative mention(s) Neutral Lyell Immunopharma 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media refer more to INBX or LYEL?

In the previous week, Lyell Immunopharma had 5 more articles in the media than Inhibrx Biosciences. MarketBeat recorded 7 mentions for Lyell Immunopharma and 2 mentions for Inhibrx Biosciences. Lyell Immunopharma's average media sentiment score of 0.39 beat Inhibrx Biosciences' score of 0.30 indicating that Lyell Immunopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inhibrx Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Lyell Immunopharma 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has stronger valuation and earnings, IMTX or LYEL?

Immatics has higher revenue and earnings than Lyell Immunopharma. Immatics is trading at a lower price-to-earnings ratio than Lyell Immunopharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Immatics $54.60M 23.93 -$222.26M -$1.99 N/A Lyell Immunopharma $40K 8,722.00 -$274.45M -$12.83 N/A

Does the media prefer IMTX or LYEL?

In the previous week, Lyell Immunopharma had 6 more articles in the media than Immatics. MarketBeat recorded 7 mentions for Lyell Immunopharma and 1 mentions for Immatics. Lyell Immunopharma's average media sentiment score of 0.39 beat Immatics' score of 0.00 indicating that Lyell Immunopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immatics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Lyell Immunopharma 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media prefer LYEL or AKTS?

In the previous week, Lyell Immunopharma had 4 more articles in the media than Aktis Oncology. MarketBeat recorded 7 mentions for Lyell Immunopharma and 3 mentions for Aktis Oncology. Lyell Immunopharma's average media sentiment score of 0.39 beat Aktis Oncology's score of 0.26 indicating that Lyell Immunopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lyell Immunopharma 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Aktis Oncology 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Lyell Immunopharma (LYEL) Competitors

$14.24 -0.47 (-3.20%)

As of 01:47 PM Eastern

Compare

LYEL vs. ABSI, NVAX, INBX, IMTX, and AKTS

Should you buy Lyell Immunopharma stock or one of its competitors? MarketBeat compares Lyell Immunopharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Lyell Immunopharma include Absci (ABSI), Novavax (NVAX), Inhibrx Biosciences (INBX), Immatics (IMTX), and Aktis Oncology (AKTS). These companies are all part of the "biotechnology" industry.

How does Lyell Immunopharma compare to Absci?

Lyell Immunopharma (NASDAQ:LYEL) and Absci (NASDAQ:ABSI) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, valuation, analyst recommendations, risk, media sentiment, earnings, dividends and institutional ownership.

Lyell Immunopharma has a beta of -0.04, suggesting that its share price is 104% less volatile than the broader market. Comparatively, Absci has a beta of 2.35, suggesting that its share price is 135% more volatile than the broader market.

Absci has higher revenue and earnings than Lyell Immunopharma. Absci is trading at a lower price-to-earnings ratio than Lyell Immunopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lyell Immunopharma	$40K	8,722.00	-$274.45M	-$12.83	N/A
Absci	$2.80M	501.39	-$115.18M	-$0.83	N/A

66.1% of Lyell Immunopharma shares are held by institutional investors. Comparatively, 52.1% of Absci shares are held by institutional investors. 6.2% of Lyell Immunopharma shares are held by company insiders. Comparatively, 10.5% of Absci shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Lyell Immunopharma had 5 more articles in the media than Absci. MarketBeat recorded 7 mentions for Lyell Immunopharma and 2 mentions for Absci. Lyell Immunopharma's average media sentiment score of 0.39 beat Absci's score of 0.00 indicating that Lyell Immunopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lyell Immunopharma	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Absci	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Absci has a net margin of -6,450.76% compared to Lyell Immunopharma's net margin of -920,285.25%. Absci's return on equity of -66.32% beat Lyell Immunopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lyell Immunopharma	-920,285.25%	-87.60%	-67.85%
Absci	-6,450.76%	-66.32%	-57.01%

Lyell Immunopharma presently has a consensus target price of $42.00, suggesting a potential upside of 194.94%. Absci has a consensus target price of $13.43, suggesting a potential upside of 49.12%. Given Lyell Immunopharma's higher probable upside, equities analysts plainly believe Lyell Immunopharma is more favorable than Absci.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lyell Immunopharma	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
Absci	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.78

Summary

Absci beats Lyell Immunopharma on 9 of the 16 factors compared between the two stocks.

How does Lyell Immunopharma compare to Novavax?

Novavax (NASDAQ:NVAX) and Lyell Immunopharma (NASDAQ:LYEL) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, media sentiment, profitability, valuation, analyst recommendations, institutional ownership, earnings and risk.

Novavax has a net margin of -59.87% compared to Lyell Immunopharma's net margin of -920,285.25%. Novavax's return on equity of -14.82% beat Lyell Immunopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novavax	-59.87%	-14.82%	-13.35%
Lyell Immunopharma	-920,285.25%	-87.60%	-67.85%

53.0% of Novavax shares are held by institutional investors. Comparatively, 66.1% of Lyell Immunopharma shares are held by institutional investors. 1.6% of Novavax shares are held by insiders. Comparatively, 6.2% of Lyell Immunopharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Novavax has a beta of 2.47, indicating that its share price is 147% more volatile than the broader market. Comparatively, Lyell Immunopharma has a beta of -0.04, indicating that its share price is 104% less volatile than the broader market.

Novavax has higher revenue and earnings than Lyell Immunopharma. Novavax is trading at a lower price-to-earnings ratio than Lyell Immunopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novavax	$1.12B	1.15	$440.30M	-$1.52	N/A
Lyell Immunopharma	$40K	8,722.00	-$274.45M	-$12.83	N/A

Novavax currently has a consensus target price of $13.00, suggesting a potential upside of 65.92%. Lyell Immunopharma has a consensus target price of $42.00, suggesting a potential upside of 194.94%. Given Lyell Immunopharma's stronger consensus rating and higher probable upside, analysts clearly believe Lyell Immunopharma is more favorable than Novavax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novavax	3 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.20
Lyell Immunopharma	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

In the previous week, Novavax had 18 more articles in the media than Lyell Immunopharma. MarketBeat recorded 25 mentions for Novavax and 7 mentions for Lyell Immunopharma. Lyell Immunopharma's average media sentiment score of 0.39 beat Novavax's score of 0.22 indicating that Lyell Immunopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novavax	5 Very Positive mention(s)	3 Positive mention(s)	9 Neutral mention(s)	4 Negative mention(s)	1 Very Negative mention(s)	Neutral
Lyell Immunopharma	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

Lyell Immunopharma beats Novavax on 9 of the 17 factors compared between the two stocks.

How does Lyell Immunopharma compare to Inhibrx Biosciences?

Inhibrx Biosciences (NASDAQ:INBX) and Lyell Immunopharma (NASDAQ:LYEL) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, dividends, media sentiment, institutional ownership, risk and earnings.

Inhibrx Biosciences has a beta of 3.51, indicating that its stock price is 251% more volatile than the broader market. Comparatively, Lyell Immunopharma has a beta of -0.04, indicating that its stock price is 104% less volatile than the broader market.

82.5% of Inhibrx Biosciences shares are held by institutional investors. Comparatively, 66.1% of Lyell Immunopharma shares are held by institutional investors. 18.3% of Inhibrx Biosciences shares are held by company insiders. Comparatively, 6.2% of Lyell Immunopharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Lyell Immunopharma had 5 more articles in the media than Inhibrx Biosciences. MarketBeat recorded 7 mentions for Lyell Immunopharma and 2 mentions for Inhibrx Biosciences. Lyell Immunopharma's average media sentiment score of 0.39 beat Inhibrx Biosciences' score of 0.30 indicating that Lyell Immunopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Inhibrx Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Lyell Immunopharma	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Inhibrx Biosciences has a net margin of 0.00% compared to Lyell Immunopharma's net margin of -920,285.25%. Lyell Immunopharma's return on equity of -87.60% beat Inhibrx Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inhibrx Biosciences	N/A	-563.90%	-72.32%
Lyell Immunopharma	-920,285.25%	-87.60%	-67.85%

Inhibrx Biosciences has higher revenue and earnings than Lyell Immunopharma. Inhibrx Biosciences is trading at a lower price-to-earnings ratio than Lyell Immunopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inhibrx Biosciences	$1.30M	998.86	-$140.05M	-$8.39	N/A
Lyell Immunopharma	$40K	8,722.00	-$274.45M	-$12.83	N/A

Inhibrx Biosciences presently has a consensus price target of $150.00, suggesting a potential upside of 69.46%. Lyell Immunopharma has a consensus price target of $42.00, suggesting a potential upside of 194.94%. Given Lyell Immunopharma's stronger consensus rating and higher probable upside, analysts clearly believe Lyell Immunopharma is more favorable than Inhibrx Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inhibrx Biosciences	1 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.33
Lyell Immunopharma	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

Summary

Lyell Immunopharma beats Inhibrx Biosciences on 9 of the 16 factors compared between the two stocks.

How does Lyell Immunopharma compare to Immatics?

Immatics (NASDAQ:IMTX) and Lyell Immunopharma (NASDAQ:LYEL) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, risk, analyst recommendations, institutional ownership, valuation and earnings.

In the previous week, Lyell Immunopharma had 6 more articles in the media than Immatics. MarketBeat recorded 7 mentions for Lyell Immunopharma and 1 mentions for Immatics. Lyell Immunopharma's average media sentiment score of 0.39 beat Immatics' score of 0.00 indicating that Lyell Immunopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immatics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Lyell Immunopharma	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Immatics has a net margin of -572.35% compared to Lyell Immunopharma's net margin of -920,285.25%. Immatics' return on equity of -47.36% beat Lyell Immunopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immatics	-572.35%	-47.36%	-39.35%
Lyell Immunopharma	-920,285.25%	-87.60%	-67.85%

Immatics has a beta of 1.33, suggesting that its stock price is 33% more volatile than the broader market. Comparatively, Lyell Immunopharma has a beta of -0.04, suggesting that its stock price is 104% less volatile than the broader market.

64.4% of Immatics shares are held by institutional investors. Comparatively, 66.1% of Lyell Immunopharma shares are held by institutional investors. 6.2% of Lyell Immunopharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Immatics has higher revenue and earnings than Lyell Immunopharma. Immatics is trading at a lower price-to-earnings ratio than Lyell Immunopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immatics	$54.60M	23.93	-$222.26M	-$1.99	N/A
Lyell Immunopharma	$40K	8,722.00	-$274.45M	-$12.83	N/A

Immatics currently has a consensus target price of $20.80, suggesting a potential upside of 113.44%. Lyell Immunopharma has a consensus target price of $42.00, suggesting a potential upside of 194.94%. Given Lyell Immunopharma's stronger consensus rating and higher possible upside, analysts plainly believe Lyell Immunopharma is more favorable than Immatics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immatics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Lyell Immunopharma	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

Summary

Lyell Immunopharma beats Immatics on 9 of the 16 factors compared between the two stocks.

How does Lyell Immunopharma compare to Aktis Oncology?

Lyell Immunopharma (NASDAQ:LYEL) and Aktis Oncology (NASDAQ:AKTS) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, earnings, dividends, institutional ownership, profitability, analyst recommendations, risk and media sentiment.

Lyell Immunopharma currently has a consensus price target of $42.00, indicating a potential upside of 194.94%. Aktis Oncology has a consensus price target of $34.60, indicating a potential upside of 42.65%. Given Lyell Immunopharma's higher probable upside, research analysts plainly believe Lyell Immunopharma is more favorable than Aktis Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lyell Immunopharma	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
Aktis Oncology	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

66.1% of Lyell Immunopharma shares are owned by institutional investors. Comparatively, 28.8% of Aktis Oncology shares are owned by institutional investors. 6.2% of Lyell Immunopharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Aktis Oncology has higher revenue and earnings than Lyell Immunopharma. Aktis Oncology is trading at a lower price-to-earnings ratio than Lyell Immunopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lyell Immunopharma	$40K	8,722.00	-$274.45M	-$12.83	N/A
Aktis Oncology	$6.50M	199.26	-$63.73M	-$0.38	N/A

In the previous week, Lyell Immunopharma had 4 more articles in the media than Aktis Oncology. MarketBeat recorded 7 mentions for Lyell Immunopharma and 3 mentions for Aktis Oncology. Lyell Immunopharma's average media sentiment score of 0.39 beat Aktis Oncology's score of 0.26 indicating that Lyell Immunopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lyell Immunopharma	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Aktis Oncology	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Aktis Oncology has a net margin of 0.00% compared to Lyell Immunopharma's net margin of -920,285.25%. Aktis Oncology's return on equity of 0.00% beat Lyell Immunopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lyell Immunopharma	-920,285.25%	-87.60%	-67.85%
Aktis Oncology	N/A	N/A	N/A

Summary

Lyell Immunopharma and Aktis Oncology tied by winning 7 of the 14 factors compared between the two stocks.

Get Lyell Immunopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LYEL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LYEL vs. The Competition

Export

Metric	Lyell Immunopharma	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$349.49M	$3.72B	$7.04B	$12.92B
Dividend Yield	N/A	3.76%	2.58%	10.20%
P/E Ratio	-1.11	9.08	269.97	24.82
Price / Sales	8,722.00	1,268.38	650.66	108.09
Price / Cash	N/A	44.95	28.89	37.44
Price / Book	1.22	17.65	11.26	6.44
Net Income	-$274.45M	-$13.25M	$3.45B	$347.27M
7 Day Performance	10.64%	5.33%	3.62%	2.55%
1 Month Performance	-5.13%	-1.83%	-0.56%	-1.02%
1 Year Performance	29.69%	61.05%	77.38%	23.33%

Lyell Immunopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LYEL Lyell Immunopharma	3.2702 of 5 stars	$14.24 -3.2%	$42.00 +194.9%	+34.0%	$349.49M	$40K	N/A	270	Earnings Report
ABSI Absci	2.6052 of 5 stars	$8.48 +6.9%	$13.43 +58.4%	+214.4%	$1.24B	$2.80M	N/A	210	Upcoming Earnings Gap Up
NVAX Novavax	2.353 of 5 stars	$7.66 +3.4%	$13.00 +69.7%	-5.0%	$1.22B	$1.12B	N/A	1,990	Earnings Report
INBX Inhibrx Biosciences	2.2011 of 5 stars	$84.17 +1.7%	$150.00 +78.2%	+321.0%	$1.21B	$1.30M	N/A	166	Upcoming Earnings Analyst Upgrade Gap Up
IMTX Immatics	1.8599 of 5 stars	$9.38 +4.0%	$20.80 +121.7%	+56.1%	$1.21B	$54.60M	N/A	260	Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LYEL) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Lyell Immunopharma (LYEL) Competitors

LYEL vs. ABSI, NVAX, INBX, IMTX, and AKTS

How does Lyell Immunopharma compare to Absci?

Summary

How does Lyell Immunopharma compare to Novavax?

Summary

How does Lyell Immunopharma compare to Inhibrx Biosciences?

Summary

How does Lyell Immunopharma compare to Immatics?

Summary

How does Lyell Immunopharma compare to Aktis Oncology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LYEL vs. The Competition

Lyell Immunopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Lyell Immunopharma (LYEL) Competitors

LYEL vs. ABSI, NVAX, INBX, IMTX, and AKTS

How does Lyell Immunopharma compare to Absci?

Which has more risk & volatility, LYEL or ABSI?

Which has higher earnings and valuation, LYEL or ABSI?

Do institutionals & insiders have more ownership in LYEL or ABSI?

Does the media prefer LYEL or ABSI?

Is LYEL or ABSI more profitable?

Do analysts prefer LYEL or ABSI?

Summary

How does Lyell Immunopharma compare to Novavax?

Is NVAX or LYEL more profitable?

Do insiders and institutionals hold more shares of NVAX or LYEL?

Which has more volatility and risk, NVAX or LYEL?

Which has higher valuation & earnings, NVAX or LYEL?

Do analysts rate NVAX or LYEL?

Does the media refer more to NVAX or LYEL?

Summary

How does Lyell Immunopharma compare to Inhibrx Biosciences?

Which has more risk & volatility, INBX or LYEL?

Do insiders & institutionals hold more shares of INBX or LYEL?

Does the media refer more to INBX or LYEL?

Is INBX or LYEL more profitable?

Which has preferable earnings and valuation, INBX or LYEL?

Do analysts rate INBX or LYEL?

Summary

How does Lyell Immunopharma compare to Immatics?

Does the media prefer IMTX or LYEL?

Is IMTX or LYEL more profitable?

Which has more volatility & risk, IMTX or LYEL?

Do institutionals and insiders hold more shares of IMTX or LYEL?

Which has stronger valuation and earnings, IMTX or LYEL?

Do analysts rate IMTX or LYEL?

Summary

How does Lyell Immunopharma compare to Aktis Oncology?

Do analysts prefer LYEL or AKTS?

Do institutionals & insiders believe in LYEL or AKTS?

Which has higher valuation and earnings, LYEL or AKTS?

Does the media prefer LYEL or AKTS?

Is LYEL or AKTS more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LYEL vs. The Competition

Lyell Immunopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools